(Q37419038)

20 August 2017

1 reference

title

Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations (English)

1 reference

20 August 2017

0 references

Eilhard Mix

1

1 reference

20 August 2017

Hans Meyer-Rienecker

series ordinal

2

1 reference

20 August 2017

Uwe K Zettl

series ordinal

3

1 reference

20 August 2017

publication date

1 December 2008

1 reference

20 August 2017

1 reference

20 August 2017

volume

255 Suppl 6

1 reference

20 August 2017

page(s)

7-14

1 reference

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-6003-0

Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis

21 January 2018

1 reference

12 December 2020

Development of cladribine treatment in multiple sclerosis

1 reference

12 December 2020

IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions

1 reference

12 December 2020

Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Central nervous system-directed effects of FTY720 (fingolimod).

1 reference

12 December 2020

Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

12 December 2020

Emerging oral therapies for multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

1 reference

12 December 2020

Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases

1 reference

12 December 2020

Ciliary neurotrophic factor: Pharmacokinetics and acute-phase response in rat

1 reference

12 December 2020

Genetics of rat neuroinflammation.

1 reference

12 December 2020

Monoclonal antibody treatments for multiple sclerosis

1 reference

12 December 2020

IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis.

1 reference

12 December 2020

The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease

1 reference

12 December 2020

Axonal protection achieved in a model of multiple sclerosis using lamotrigine

1 reference

12 December 2020

Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug

1 reference

12 December 2020

Stem cell therapy in patients with multiple sclerosis

1 reference

12 December 2020

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

1 reference

12 December 2020

Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis

1 reference

12 December 2020

Identification and development of new therapeutics for multiple sclerosis

1 reference

12 December 2020

Hydroxyzine inhibits experimental allergic encephalomyelitis (EAE) and associated brain mast cell activation.

1 reference

12 December 2020

Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor

1 reference

12 December 2020

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

1 reference

12 December 2020

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis

1 reference

12 December 2020

The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse

1 reference

12 December 2020

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

1 reference

12 December 2020

K(+) channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis

1 reference

12 December 2020

B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

1 reference

12 December 2020

Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine

1 reference

12 December 2020

Neural stem cells: guardians of the brain

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

ALLERGIC ENCEPHALOMYELITIS IN MONKEYS IN RESPONSE TO INJECTION OF NORMAL MONKEY NERVOUS TISSUE.

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS

1 reference

12 December 2020

Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis.

1 reference

12 December 2020

Vaccines for multiple sclerosis: progress to date

1 reference

12 December 2020

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

1 reference

12 December 2020

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

1 reference

12 December 2020

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

1 reference

12 December 2020

A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis

1 reference

12 December 2020

Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

12 December 2020

1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking

1 reference

12 December 2020

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

12 December 2020

T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy

1 reference

12 December 2020

Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Oral tolerance: therapeutic implications for autoimmune diseases

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations

1 reference

12 December 2020

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

1 reference

12 December 2020

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

1 reference

12 December 2020

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination

1 reference

12 December 2020

2-Chloro-2'-deoxyadenosine: alteration of DNA:TATA element binding protein (TBP) interactions

1 reference

12 December 2020

Campath-1H treatment of multiple sclerosis

1 reference

12 December 2020

Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.

1 reference

12 December 2020

Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis.

1 reference

12 December 2020

Time-course expression of CNS inflammatory, neurodegenerative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

1 reference

12 December 2020

Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE.

1 reference

12 December 2020

Encephalomyelitis in the rat following intracutaneous injection of central nervous system tissue with adjuvant

1 reference

12 December 2020

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease prom

1 reference

12 December 2020

Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020

The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis

1 reference

12 December 2020

Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis.

1 reference

12 December 2020

Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Gene therapy-mediated modulation of immune processes in the central nervous system

1 reference

12 December 2020

Geranylgeranylation but not GTP-loading of Rho GTPases determines T cell function

1 reference

12 December 2020

Oral disease-modifying treatments for multiple sclerosis: the story so far.

1 reference

12 December 2020

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

12 December 2020

Experimental disseminated encephalomyelitis in white mice

1 reference

12 December 2020

Treating multiple sclerosis with monoclonal antibodies

1 reference

12 December 2020

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

12 December 2020

Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis

1 reference

12 December 2020

IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment

1 reference

12 December 2020

Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

1 reference

12 December 2020

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

12 December 2020

Axonal protection using flecainide in experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

1 reference

12 December 2020

Getting specific: monoclonal antibodies in multiple sclerosis.

1 reference

12 December 2020

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-008-6003-0

Identifiers

DOI

1 reference

20 August 2017

1 reference